Merck vioxx recall case study
Common Questions and Answers about Merck vioxx recall case study
vioxx
There was no money exchanged or special consideration given to get Vioxx on the market. However, Vioxx is a good example of a study not digging deep enough into long term effects of a new drug. Vioxx was introduced in 1999 and was originally thought of as a treatment for polyps in the intestinal track.
I am a occupational therapy student and have a case study on an 8 year old boy who has developed enuresis at night, he has started to soil himself, as a result is being bullied at school, he is reluctant to go to school and complains of physical symptoms stomach ache and head ache
his mother died at the age of five, his dad has recently started a new relationship
please can you help, give any suggestions as to why he may being doing these things
I am on the list for the Merck study. I have done the screening and will know if I am accepted within a week or so. It is already underway and added a few new slots on Aug 27th. Would love to hear from anyone already doing the study. The coordinator at the center said it is going great with no viral load within two weeks on most of the people.
Fret, I know you quit pretty early, but they invited you to this study as I recall. How long did you take Bocep and did you get a decent log drop in that time? Have you received any info on mutations?
Maybe this FDA announcement will make something happen. I am going to start a new thread asking if anyone has gotten mutation info from Merck on any Boceprevir trial.
Thanks!
I will know then if that is EOT or I go for 6 more weeks. The Merck trial presented wonderful results at the ASSLD conference. 97 out of 98 reached SVR. That was a 12 week study but did not include hard to treat such as null responders, cirrhotics and HIV. These new drugs are changing the way Hep C is treated---rapidly. The future looks bright for all of us. Still have a way to go, but I am optimistic about my trial and others.
Thu Apr 10, 2014 1:17am EDT (Reuters) - A two-drug combination being tested by Merck & Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.
Results of the study called C-Worthy were presented on Thursday at the annual meeting of the European Association for the Study of the Liver (EASL) in London.
So a couple of months is a good projection as this pill changes hormonal balance in your blood and gene expression about androgen receptors. There is a Swedish study that states the permanent dangers of this drug :
In 2008, the Swedish Medical Products Association reported that men who used Propecia may be more likely to suffer from irreversible sexual dysfunction. The organization soon required that Merck updated the safety labeling to include this important risk information.
I remember a previous study, with a protease and NS5A that did not do so well with just the two drugs (BMS compounds). The recent Merck study results (interim results) are amazing, hard to believe the drugs are in the same class as the BMS drugs. It should be pointed out that the results I saw were for the C-Worthy study, and it seems to me they only used treatment naive patients. I wonder if the results will look as good when tested against relapsers and non-responder genotype 1a/1b.
The likely reason for the difference was in the first study (ELECTRON) 44% of of patients had the IL28B CC polymorphism.
The second study (QUANTUM) only had 16 percent of the patients with CC.
Yes, there are many non-interferon drugs in trials. But Gilead GS-7977 is the furthest along in trials. Which is why it is expected to be the first to market.
Cheers!
The Arlington Center did the study this last Spring for Gilead, Gilead did a biopsy and found that I had cirrhosis so was rejected. I was just screened for a Merck study there last Tuesday and am waiting to hear if I am accepted. Really nice staff at this center. Just call the centers and see if the have anything coming up.
http://www.lifewhile.com/health/5064766/detail.html. Recent data regarding another HPV vaccine, Cervarix, has demonstrated equal HPV protection with fewer than 3 doses, and even comparable efficacy in single doses.
So my question is this: who is right? Dr. Handsfield, or the Merck representative quoting data from a formal study? This isn't meant to sound rude. I'm just honestly trying to understand why Dr. Handsfield (who is an STD expert) disagrees with the study, and why.
Merck is working on a vaccine and it is successful.
They now have the Cervical Cancer Vaccine ( Gardasil) and are working on an OVCA vaccine. They are in the second trial and need one more before the FDA approves. By giving it to patients with OVC in recurrence, they have prevented it from returning for two years. They are tweeking that and want total prevention. They have also been successful with prostrate cancer and as you heard last week, skin cancer.
Just in case you haven't heard, hummus and other dips sold at Trader Joe's and Target have been recalled due to possible Listeria contamination.
Be Careful Ladies!!!
7 million to be paid by Merck. Before anyone feels bad for Merck, he or she should also know that some researchers estimate that Merck “earned” about $3 billion (with a “b”) in 2007 from Fosamax. There are still many unsettled suits.
While alendronate sodium does have some appropriate indications, there are serious side effects which can occur. Most of the lawsuits focus on one of two harms – femur fractures or osteonecrosis of the jaw.
Recommended
